Latest Sunitinib Stories
WALTHAM, Mass., Feb.
A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract.
WAYNE, N.J. and EMERYVILLE, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc.
PHILADELPHIA, Oct. 19 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved VOTRIENT(TM) (pazopanib) to treat patients with advanced renal cell carcinoma (RCC), a form of kidney cancer.
SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S.
Perifosine Continues to Demonstrate Impressive Efficacy, Safety and Tolerability in Metastatic Renal Cell Carcinoma Patients who Progressed after Failing Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor QUEBEC CITY, Sept.
NEW YORK, Sept. 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
NEW YORK, Sept. 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
WALTHAM, Mass., Sept.14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent.
NEW YORK, Sept.
- To swell, as grain or wood with water.